King Wealth Management Group’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

King Wealth Management Group’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-27,000	Closed	-$90K	–	162
2019 Q4	$90K	Hold	27,000	–	–	0.02%	140
2019 Q3	$82K	Buy	27,000 +7,000	+35%	+$19.7K	0.02%	142
2019 Q2	$48K	Buy	+20,000	New	+$59.8K	0.01%	135
2019 Q1	–	Sell	-34,000	Closed	-$122K	–	143
2018 Q4	$122K	Buy	34,000 +13,500	+66%	+$58.7K	0.04%	126
2018 Q3	$117K	Buy	+20,500	New	+$117K	0.04%	130

King Wealth Management Group's FOMX Position: Q1 2020 in Review

King Wealth Management Group sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 27,000 shares — an estimated $90K sold.

King Wealth Management Group first reported a position in FOMX in Q3 2018 and held it in 5 quarters. The position peaked at $122K in Q4 2018. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.

King Wealth Management Group reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
King Wealth Management Group sold 27,000 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $90K.
King Wealth Management Group first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2018 and held it in 5 quarters.
King Wealth Management Group's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $122K in Q4 2018.
3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.

Based on King Wealth Management Group's 13F filing for Q1 2020, filed 13 May 2020.